Antidepressant pharmacologic treatments;Tratamientos farmacológicos antidepresivos

Revista Chilena de Neuro-Psiquiatria

Volumn 40, Issue SUPPL. 1, 2002, Pages 21-45

  Heerlein, Andrés ^a  

^a UNIVERSIDAD DE CHILE   (Chile)

Author keywords

Major depression; Psychopharmacology; Treatment

Indexed keywords

AMFEBUTAMONE; AMITRIPTYLINE; AMOXAPINE; ANTICONVULSIVE AGENT; ANTIDEPRESSANT AGENT; ANTIHYPERTENSIVE AGENT; CISAPRIDE; CLONIDINE; DOXEPIN; DULOXETINE; LIDOCAINE; METHYLPHENIDATE; MILNACIPRAN; MIRTAZAPINE; MOCLOBEMIDE; NEFAZODONE; NORTRIPTYLINE; PHENYTOIN; PIRLINDOLE; PREGABALIN; PROPRANOLOL; QUINIDINE; REBOXETINE; SEROTONIN UPTAKE INHIBITOR; TRICYCLIC ANTIDEPRESSANT AGENT; TRIMIPRAMINE; VENLAFAXINE;

AGITATION; AGRANULOCYTOSIS; AKATHISIA; ALBUMINURIA; ALLERGIC REACTION; ALOPECIA; ANOREXIA; ANORGASMIA; ARTERITIS; ASTHENIA; CONGESTIVE HEART FAILURE; CONSTIPATION; CONVULSION; DIARRHEA; DRUG ACTIVITY; DRUG EFFICACY; DYSTONIA; EOSINOPHILIA; EPIGASTRIC PAIN; EXTRAPYRAMIDAL SYMPTOM; FACE EDEMA; FATIGUE; GALACTORRHEA; GASTROINTESTINAL SYMPTOM; GINGIVITIS; GLAUCOMA; GLUCOSURIA; GYNECOMASTIA; HEART ARRHYTHMIA; HEART DISEASE; HEART INFARCTION; HEMATURIA; HEPATITIS; HUMAN; HYPERCHOLESTEROLEMIA; HYPERLIPIDEMIA; HYPERPYREXIA; HYPERTENSION; HYPERTRICHOSIS; HYPERURICEMIA; HYPOCALCEMIA; INSOMNIA; LEUKOPENIA; LONG TERM CARE; MAJOR DEPRESSION; MEDICAL RESEARCH; MENSTRUAL IRREGULARITY; MIGRAINE; NAUSEA; ORTHOSTATIC HYPOTENSION; PARKINSONISM; PHOTOSENSITIVITY; PSORIASIS; PSYCHOSIS; PSYCHOTHERAPY; QT PROLONGATION; RASH; REVIEW; SEDATION; SEROTONIN SYNDROME; SEXUAL DYSFUNCTION; SIDE EFFECT; SOMNOLENCE; SUICIDE; TACHYCARDIA; THROMBOCYTOPENIA; URINE RETENTION; VERTIGO; VOMITING;

EID: 31544458180     PISSN: 00347388     EISSN: 07179227     Source Type: Journal    
DOI: None     Document Type: Review

References (26)

1. Gastpar M. Antidepressiva. Stuttgart, Georg Thieme Verlag, 1998
2. Roca M. Trastornos del Humor. Madrid, Editorial Médica Panamericana, 2000
3. Jufe G. Psicofarmacología Práctica. Buenos Aires, Editorial Polemos, 2001
4. Heerlein A. Antidepresivos. En: Heerlein A (ed): Psiquiatría Clínica. Santiago de Chile, Ediciones de la Sociedad de Neurología, Psiquiatría y Neurocirugía, 2000
5. Stahl S. Mechanism of Antidepressant Action. J Clin Psychiatry 1998; 59:5-14
6. Blier P, Bergeron R. Possible neurobiological mechanism underlying faster onset of antidepressant action. J Clin Psychiatry 2001; 62: 7-11
7. Mallei A, Shi B, Mocchetti I. Antidepressant treatments induce the expression of basic fibroblast growth factor in cortical and hippocampal neurons. Mol Pharmacol 2002; 61(5):1017-24
8. Leonard B. New approaches to the treatment of depression. J Clin Psychiatry 1996; 57:26-33
9. Mendels J, Camera A, Sikes C. Sertraline treatment for premature ejaculation. J Clin Psychopharmacol 1995; 15:341-6
10. Ling F. Recognizing and treating premenstrual dysphoric disorder in the obstetric, gynecologic, and primary care practices. J Clin Psychiatry 2000; 61:9-16
11. Benkert O, Hippius H. Psychiatrische Pharmakotherapie. Berlin, Heidelberg, New York, Tokyo, Springer-Verlag, 1986
12. Bech P. Acute therapy of depression. Compr Psychiatry 1993; 54: 18-27
13. Danish University Antidepressant Group: Paroxetine: a selective serotonine reuptake inhibitor showing better tolerance but weaker effect than clomipramine in a controlled multicenter study. J Affect Disord 1990; 18:289-99
14. Thompson C. Mirtazapine versus selective serotonin reuptake inhibitors. J Clin Psychiatry 1999; 60:18-22
15. Pesola GR, Avasarala J. Bupropion seizure proportion among new-onset generalized seizures and drug related seizures presenting to an emergency department. J Emerg Med 2002; 22(3):235-9
16. Amchin J, Ereshefsky L, Zarycranski W, Taylor K, Albano D, Klockowski PM. Effect of venlafaxine versus fluoxetine on metabolism of dextromethorphan, a CYP2D6 probe. J Clin Pharmacol 2001; 41(4):443-5
17. Mayberg HS, Brannan SK, Tekell JL et al. Regional metabolic effects of fluoxetine in major depression: serial changes in relationship to clinical response. Biol Psychiatry 2000; 48:830-43
18. Detke MJ, Lu Y, Goldstein DJ, Hayes JR, Demitrack MA. Duloxetine, 60 mg once daily, for major depressive disorder: a randomized double-blind placebo-controlled trial. J Clin Psychiatry 2002; 63(4):308-15
19. Goldstein DJ, Mallinckrodt C, Lu Y, Demitrack MA. Duloxetine in the treatment of major depressive disorder: a double-blind clinical trial. J Clin Psychiatry 2002; 63(3):225-31
20. Tordera RM, Monge A, Del Rio J, Lasheras B. Antidepressant-like activity of VN2222, a serotonin reuptake inhibitor with high affinity at 5-HT(1A) receptors. Eur J Pharmacol 2002; 442(1-2):63-71
21. American Psychiatric Association: Practice Guideline for the Treatment of Patients with Major Depressive Disorder (Revisión). Am J Psychiatry 2000; 157: 4 (Supplement)
22. Frank E, Kupfer D, Perel J et al. Three-year outcomes for maintenance therapies in recurrent depression. Arch Gen Psychiatry 1990; 47:1093-9
23. Heerlein A. Personalidad y depresión. En: Retamal P (ed). Los Trastornos Depresivos. En prensa
24. Fava M, Davidson KG. Definition and epidemiology of treatment-resistant depression. Psychiatr Clin North Amer 1996; 19:179-95
25. O'Reardon JP, Brunswick DJ, Amsterdam JD. Treatment -resistant depression in the age of serotonin: evolving strategies. Current Opinion in Psychiatry 2000; 13: 93-8
26. Goodwin FK, Jamison KR. Manic Depressive Illness. New York, Oxford University Press, 1991